In this article (Clin Cancer Res 2014;20:3222–32), which was published in the June 15, 2014, issue of Clinical Cancer Research (1), the corresponding author informed us of a nomenclature error in the published article. The primary chemical form of the drug used in each of the in vitro and in vivo experiments presented in the study was chloroquine (CQ) diphosphate and not hydroxychloroquine (HCQ) diphosphate as reported in the text. CQ is chloroquine diphosphate (Sigma-Aldrich, catalog number: C6628), i.e., N4-(7-chloro-4-quinolinyl)-N1,N1-dimethyl-1,4-pentanediamine diphosphate salt); Sigma does not sell HCQ diphosphate. Hydroxychloroquine is a hydroxyl derivative of chloroquine. The conclusions put forth in this article remain unchanged.
The online version of this article has been changed to reflect the correct nomenclature and no longer matches the print version. The authors regret this error.
RSS Feeds